Our committees continue to work hard to advance the interests of Society members. Thank you to all of the committee chairs for their tireless efforts. In 2013, the Socioeconomics Committee has been chaired by David Wazer, MD; Brad Prestidge, MD worked on External Relations and resident education. Zoubir Ouib, MS serves as chair of the Physics Committee, and Steve Frank, MD chairs the Cost Effectiveness Committee.
Most recently, the chair of our Bylaws Committee, John Hayes, MD, has stepped down and will join the newly formed International Committee. John's successor, Sushil Beriwal, MD, has already made efforts to ensure that changes to the Society are reflected in our bylaws. In order to address our multiple interactions with colleagues around the world, a new International Committee has been established, and Beth Erickson, MD has kindly agreed to chair this new effort.
We continue to work closely with our industry partners and appreciate their great support. The Nucletron resident week-long training program continues, as does their continued support of our contouring programs at the schools. Varian has been a strong supporter of our annual meeting and of our schools, also supplying computers for contouring workshops. Thank you to all of the vendors attending our meetings and providing services for our membership.
We look forward to the advances and challenges of 2014, knowing that the ABS continues to advance science and education in the area of brachytherapy.
Akila N. Viswanathan, MD, MPH

President
The Need to Tell "Our Story"
Daniel G. Petereit, MD, FASTRO
The ABS 2013 spring meeting was one of the best radiation oncology meetings I have attended in years. It was well organized, informative, and practical. A special thanks to the scientific program committee for their time and dedication.
The development and maintenance of brachytherapy skills is an ongoing goal and challenge for the ABS. I found the debate between Drs. Kuske and Smith intriguing and provocative. The 2012 JAMA publication by Smith et al using SEER data demonstrated a 4% mastectomy rate for patients undergoing APBI vs 2% for those treated with whole-breast radiation (WBI).
1 In addition, Presley et al (JCO 2012) , reported a doubling of the complication rates for women treated with APBI vs WBI.
2 Both publications and the ABS debate highlight relevant issues such as implementation of new technologies, physician and patient motivation, and ultimately, providing the best treatment and options for our patients. Similar to the implementation of permanent seed prostate brachytherapy in the 1990s, what factors influence the practicing radiation oncologist to begin offering these new services, especially, if they emerge after one's training? I found the geographic map, Figure 1 , in the Presley article most intriguing as it appears to accurately depict brachytherapy practice patterns in the US.
2 Even more intriguing, it accurately reports the evolution of APBI where I live: western, South Dakota and the adjacent states. So, at the risk of sounding self-serving, I would like to "tell my story".
After spending 10 years of the University of Wisconsin-Madison where I did my training and was on staff for 5 years as the gynecologic radiation oncologist, I decided to move back to my home state of South Dakota for both personal and professional reasons. The western part of South Dakota is medically underserved with a high percentage of medicare and medicaid patients, greatly influenced by the presence of 3 of the largest Indian Reservations where 80,000 to 100,000 American Indians live -the Lakota Sioux Nation. This area has historically had one of the highest mastectomy rates in the nation (>98%, Dartmouth Report 1996), 3 driven in part by distance from the cancer center, 150 miles or more for many, lack of cancer screening and lack of access to innovative technologies such as APBI. In 2002, we successfully competed for an NCI grant where one of the primary objectives was to offer shorter courses of radiation using IMRT and brachytherapy for prostate and breast cancer, as well as other objectives including the identification of barriers to cancer screening and treatment, comprehensive patient navigation at the cancer center and the reservations, and an ATM trial to decipher a potential molecular explanation for apparent higher acute and late toxicities for American Indians undergoing radiotherapy. 4 -5 The personal challenge was to develop brachytherapy skills for both prostate and breast cancer. The collaboration with UW-Madison was paramount in learning interstitial and intracavitary breast brachytherapy. Dr. Robert Kuske, Dr. Rakesh Patel and their staff provided the necessary training, as well as proctoring cases in Rapid City. The ABS schools and the Seattle Prostate Institute were also key resources. After two years of training, the first breast brachytherapy patient was treated using the interstitial technique. The majority of patients were treated this way until the intracavitary technique became more widely used. All patients were treated on a phase II clinical trial where detailed assessment of dosimetry, peer review, and clinical outcomes were assessed. To date, nearly 100 patients have been treated with clinical outcomes comparable to other institutions (formal analysis underway).
In parallel with the implementation of comprehensive brachytherapy services, an extensive cancer screening program was developed by our patient navigators, including a dedicated breast navigator. To date, our program has facilitated over 1,700 cancer screenings for screen detectable cancers. Our mastectomy rates have dropped from over 98% in the early 1990s to less than 20%.
While patients in our region were offered participation in the B-39 study, the majority chose to enroll in our phase II breast brachytherapy trial, as for many, the option was a mastectomy or APBI due to the distance they lived from the cancer center. Patient satisfaction scores are high, infection rates are much lower than those reported by Presley, and no one has had a mastectomy for a treatment failure or complication.
While one cannot assess physician or patient motivation from the SEER database (Smith GL) or the Centers for Medicare and Medicaid Services Chronic Condition Warehouse database (Presley CJ), my personal experience over the last 10 years suggests APBI is an excellent option for well selected patients. We in the ABS need to maintain our high standards for offering quality brachytherapy services, and to make certain "our story" is being told so as to advocate for our patients. The 2014 Winter School on Quality Management in Brachytherapy will be held February 7 -8 at the Renaissance Orlando. This will be our third QA School. We are currently working on some great new topics to maintain and improve everyone's patient safety program in brachytherapy. Please check the ABS website for further information and make sure you save those dates. This School is for physicists, Dosimetrists and radiation oncologists. Perhaps you can also build-in a family vacation in warm Orlando before or after the School -as you know there are endless family parks and entertainment options to enjoy.
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We are also working on the Q.A. forms for brachytherapy. Some of these forms have been downloaded (GYN and prostate) and can be seen on the ABS website. We intend to complete all of them before the end of the year. We welcome any member to send us comments (any) regarding these forms. Keep in mind these are still a work-in-progress and we thank you for your patience. Please check the ABS website for more information under the Physics Corner section.
We are looking forward to a great School next February in warm Orlando AND we invite our physics colleagues to send in your abstracts for the ABS 2014 Annual Meeting in San Diego (April 3 -5) -the abstract deadline is November 14 -see the ABS website to complete your abstract submission (www.americanbrachytherapy.org).
Best, Zoubir Ouhib, MS ABS Physics Committee Chair
The Need to Tell "Our Story" 
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ABS Activities and Operations continued
Medicine and is board-certified in therapeutic radiology. He is a former breast cancer fellow at Harvard Medical School where he was also on staff before returning to Michigan in 1990. He has done extensive research primarily for targeting radiation with greater precision for women with early-stage breast cancer and on reducing short and long-term morbidities associated with these treatments.
Dr. Vicini has been involved in numerous national clinical studies involving breast and prostate cancer and has designed and developed numerous phase I/II trials to evaluate low-dose rate and high-dose rate brachytherapy as the sole method of radiation therapy for selected patients with Stage I & II breast carcinoma as well as 3D conformal external beam RT APBI. He was the Principle Investigator for RTOG 0319 which was a phase II study exploring the use of 3D conformal external beam irradiation to the lumpectomy cavity alone for selected patients with early stage breast cancer. He is currently the Principal Investigator for the national NSABP B39/RTOG 0413 phase III study comparing partial breast irradiation (PBI) versus whole breast irradiation. He is also the PI for a second phase III trial from the NCI to investigate accelerated whole breast irradiation with a concurrent boost versus standard therapy for women with early stage breast cancer. His research continues to focus on improving therapeutic outcomes for all stages of breast cancer and to reduce treatment times and minimize damage to healthy tissue and vital organs. Innovations have included the development of breath hold techniques to reduce or minimize long-term cardiac toxicity in women treated with left-sided breast cancer and the use of IMRT to reduce acute radiation toxicities to the skin and late toxicities to prevent breast and arm edema, lung and heart related morbidity in women treated for breast cancer. Dr. Vicini has authored over 200 articles on breast and prostate cancer which have been published in numerous different scientific, peer-reviewed journals and has presented his research at national and international meetings as well as a Visiting Professor in the United States and Europe. He has also authored multiple chapters in textbooks and is on the editorial board of several oncology journals including Cancer, the Journal of Clinical Oncology and the Journal of the National Cancer Institute. Dr. Vicini has also With our prostate solutions, it's reality.
We believe that brachytherapy should be performed in one place to avoid patient movement and minimize shifting of the implant and targets during the procedure. So, we've developed solutions that offer clinicians a powerful tool to deliver the highest possible quality treatment planning, needle implantation and treatment delivery in a single session.
By integrating imaging and treatment in space and time, adaptive, on-the-fly planning becomes possible, enabling clinicians to optimize therapy to the greatest possible extent 1 .
[1] Hinnen K. IJROBP 2010; 76 (5) 
ABS Annual Meeting Returns to Sunny San Diego
The ABS will conduct its 2014 Annual Meeting in New Orleans at the Hyatt Regency, April 18 -20, the same site as the 2011 Annual Meeting. Our theme will be: Great ExpectationsEfficient, Effective and Economical: …Brachytherapy. Dr. Catheryn Yashar with the University of California, San Diego, will serve as the Scientific Program Chair. Included again next year will be:
• presentation of the ABS Ulrich Henschke Award, the highest award bestowed by the society, to a deserving brachytherapy practitioner
• Resident Travel Grants awarded
• Judith Stitt Awards for the Four Best Abstracts
• Thursday ABS Membership Luncheon and Business Meeting
• Thursday evening welcome reception in the exhibit hall for networking
• an extensive exhibit hall with brachytherapy product vendors
• CME and CAMPEP credits for attendees, as well as credits for dosimetrists
• Diverse topics on all disciplines presented in debates, workshops, contouring sessions, and panels, featuring distinguished experts and practitioners
• Audiotaping of presentations, coupled with speaker PowerPoints, for purchase pre-meeting, at the meeting and post-meeting • Physics (Zoubir Ouhib, MS)
• Residents (Seth Miller, MD)
• Socioeconomics (David E. Wazer, MD)
ABS Socioeconomic Committee Update
The ABS is seeking a more active role on current socioeconomic issues such as third-party reimbursement, the aggressive reemergence of capitation, and RBOM's entering the brachytherapy market. Avenues to have the ABS serve as an advocate for policies favorable to brachytherapy were recently approved at ABS Board Meetings, including the hiring of a parttime healthcare consultant who specializes in reimbursement and legislative issues. The committee includes the involvement of industry representatives as well (via the collaborative organization CAB), at the same time managing any conflicts of interest. The committee is currently led by Dr. David Wazer, and those with applicable experience and input should contact Dr. Wazer to join the committee (dwazer@tuftsmedicalcenter.org). Currently the committee is reviewing the CMS 2014 proposed rules, which again are not favorable for radiation oncology, including brachytherapy, freestanding centers and hospitals as well. Once again, the ASBS will serve as a co-sponsor, as we look to attract more surgeons to our meetings. Register on-line now to attend and review the agenda and speakers on-line as well.
ABS GYN School Held in Chicago
ABS Planning February 2014 Physics School on QA in Brachytherapy
The ABS the AS will conduct its second QA School February 7 -8, 2014 in Orlando at the Renaissance Seaworld. Zoubir Ouhib will serve as Chair. While physics-oriented, this is a School for radiation oncologists as well. 
Future ABS Meetings
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